ofONJ [6] [7] [8] ,althoughsuchreportsinthecontextofthelarge phaseIIItrialsoftheseagentsarelacking.Thesereportsincludedpatientstreatedwithsunitinib,aninhibitorofthetyrosinekinasesofVEGF,PDGF,c-kit,FLT3andRET,orbevacizumab,amonoclonalantibody,whichsolelyinhibitsVEGF. Taken together these reports underline the importance of VEGFinthedevelopmentofONJ.ThereportofBozasetal. [9] inthisissueofOnkOlOgieaddstothisinformation,since theirpatientwasalsotreatedwithsunitinib.
Therearetwoobservationsinthisreport,whichareworth mentioning.TheoccurrenceofONJwasunexpectedlyrapid: afterthefirstinfusionofzoledronicacid.Thisisinsharpcontrastwiththealmost2yearsmediantimetothedevelopment of ONJ, reported in the literature. The patient had already beenreceivingsunitinibfor5months,whichsuggestsasynergisticeffectbetweensunitinibandzoledronicacid.Theother interestingobservationisthefactthatcompleteresolutionof ONJwasachieved.Datafromtheliteraturesuggestthathealing is not usually achieved and the typical course of ONJ is thatofremissionsandrelapses [1, 10] .WhetherONJassociatedwithanti-angiogenicfactorsismoreeasilyreversibleor thefactthatthepatienthadreceivedonlyonezoledronicacid infusionmayhaveplayedaroleinthesuccessfulmanagement ofthiscomplicationcannotbedeterminedfromtheavailable datasofar.
Whatisthesignificanceofthesereportsandwhataretheir therapeutic implications? First, the true magnitude of the problem is unknown. As shown in the case of bisphosphonates, prospective evaluation is necessary to accurately estimatetheincidenceofONJ [1, 10] .Suchinformationregarding anti-angiogenic agents are lacking. In the light of these reports should the concurrent administration of bisphosphonatesandanti-angiogenictherapiesbere-evaluated?Taking into consideration the extremely limited available data the answeris:no.Nevertheless,severalrelevant issuesshouldbe takenintoaccount.Anti-angiogenictherapyrepresentsanefBisphosphonates are widely used for the treatment of bone disease in multiple myeloma and solid tumors. Side effects consist of pyrexia, renal function impairment, and hypocalcemia. Recently, a new complication has been described: avascular osteonecrosis of the jaw (ONJ). The risk of this complication is related to the type of bisphosphonate (it is higher with zoledronic acid compared to pamidronate) and thedurationoftherapy [1] .Uptonowthemajorprecipitating factorassociatedwithitsdevelopmentisthehistoryofrecent dentalproceduresortrauma.Thisledtotheendorsementof oral hygiene, avoidance of invasive dental procedures and assessment by experienced medical staff as guidelines for patients receiving bisphosphonates by various Dental and MedicalAssociations [2, 3] .
Themechanismsunderlyingthedevelopmentofthiscomplication are not fully understood. Bisphosphonates can derange repair and remodelling mechanisms which are mobilizedbyoralmucosafollowingmucosalinjuryandtheresultingmicrobialinsult.Thecontinuous,verypotentdecreasein bone turnover caused by zoledronic acid may lead to increased bone fragility and, in combination with other local factors that are present in the jaw, to the development of ONJ.Inaddition,impairedbloodsupplyhasbeenimplicated inthedevelopmentofONJ.Therehavebeenseveralreports indicatingthatzoledronicacidhasanti-angiogenicactivity [4, 5] .Thus,theinhibitionofcapillaryangiogenesismayleadto thedevelopmentofONJ.Itisreasonabletoassumethatthe additionofanantiangiogenicfactorwillactsynergisticallyto bisphosphonates in that respect. Both vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF)havebeensuggestedtoplayaroleintherepairand remodelling of maxillofascial bone. Therefore, inhibition of these agents may, theoretically, contribute to the developmentofONJ.
A number of case reports are supporting the notion that inhibitionofangiogenicfactorsmaybeaprecipitatingfactor AvascularOsteonecrosisoftheJawasa SideEffectofBisphosphonateTreatment fective form of treatment for several malignancies. These agents are not known to cause ONJ by themselves but they mayratheraugmentthiseffectof bisphosphonates.Thelatter arealsousedincasesofbonemetastasesbuttheyarenotindicatedforallpatientswiththismanifestation.Inmostsolid tumors they are indicated only for symptomatic disease. Therefore,itisessentialthattheyarenotusedoutsidetheir indication because in this case many patients may be at increasedriskofONJunnecessarily.
Until more data on ONJ associated with the use of antiangiogenicagentsareavailable,itisimportantthatpreventive measures, indicated by various medical and dental associationsregardingtheuseofbisphosphonates,arerigorouslyimplemented.Thesemeasureshavebeenshowntosignificantly decreasetheincidenceofONJinmultiplemyelomaaswellas breastcancer [11] .Thereisnoreasontobelievethattheywill notbeeffectiveinthecontextofanti-angiogenictherapy.
